+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07540988

Evaluating Nerandomilast Versus Placebo in Adults With Fibrosing Interstitial Lung Disease at Risk for Progression

Led by Boehringer Ingelheim · Updated on 2026-10-28

466

Participants Needed

162

Research Sites

1 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying adults with fibrosing interstitial lung disease ILD, excluding idiopathic pulmonary fibrosis IPF, who have been diagnosed within the last three years and may be at risk of developing progressive pulmonary fibrosis PPF. The trial aims to evaluate the effects of a medicine called nerandomilast in slowing lung function decline and disease progression in this group. Participants are randomly assigned to one of two groups one takes nerandomilast tablets, and the other takes placebo tablets that look identical but contain no medicine. The study lasts up to about 2 years and 4 months, during which participants take their assigned tablets regularly and undergo scheduled assessments to monitor their lung condition. Throughout the study, participants visit the study site regularly for tests including spirometry to measure forced vital capacity FVC and diffusing capacity of the lungs for carbon monoxide DLCO. High-resolution computed tomography HRCT scans track lung changes over time. Researchers compare these results between groups to assess treatment effects, while monitoring overall health and any side effects.

CONDITIONS

Brief Title

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

Research Team

B

Boehringer Ingelheim

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here